Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-12
2005-07-12
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S315000, C514S317000, C514S330000, C514S345000, C514S381000, C514S556000
Reexamination Certificate
active
06916821
ABSTRACT:
mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
REFERENCES:
patent: WO 00/24395 (2000-05-01), None
patent: WO 00/62771 (2000-10-01), None
patent: WO 01/02342 (2001-01-01), None
patent: WO 01/10846 (2001-02-01), None
patent: WO 01/12627 (2001-02-01), None
patent: WO 01/14390 (2001-03-01), None
Varney, M.A. et al., “SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotropic Glutamate Receptor Type 5”, Journal of Pharmacology and Experimental Therapeutics, vol. 290, No. 1, pp 170-181, 1999.
O'Leary, D. M. et al., “Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA antagonism”, British Journal of Pharmacology, 131, pp 1429-1437, 2000.
Weiler, I.J. et al., “Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation,” Proc. Natl. Acad. Sci., vol. 94, pp 5395-5400, May 1997.
Grauer, S. M. et al., Psychopharmacology, vol. 141, No. 4, pp. 405-412, Feb. 1999.
Pepeu, G., “Memory Disorders: Novel Treatments, Clinical Perspective,”Life Sciences.55(25/26):2189-2194 (1994).
Bartus, R. T., “Drugs to Treat Age-Related Neurodegenerative Problems: The Final Frontier of Medical Science?”J. Am. Geriatr. Soc.38(6):680-695 (1990).
Bordi, F., et al., “Group I Metabotropic Glutamate Receptors: Implications for Brain Diseases”,Prog. Neurobiol.,59(1):55-79 (1999).
Knöpfel, T., et al., “Metabotropic Glutamate Receptors: Novel Targets for Drug Development”,J. Med. Chem.,38(9):1417-1426 (1995).
Oka A., et al., “The Up-regulation of Metabotropic Glutamate Receptor 5 (mGluR5) in Down's Syndrome Brains,”Acta Neuropathol.,97(3):275-278 (1999).
Greenough, W.T., et al., “Synaptic Regulation of Protein Synthesis and the Fragile X Protein,”Proc. Natl. Acad. Sci. USA,98(13):7101-7106 (2001).
Grauer, S.M., et al., “Intracerebral Administration of Metabotropic Glutamate Receptor Agonists Disrupts Prepulse Inhibition of Acoustic Startle in Sprague-Dawley Rats,”Psychopharmacology,141:405-412 (1999).
Snyder, E.M., et al., “Internalization of Ionotropic Glutamate Receptors in Response to mGluR Activation,”Nature Neurosci.,4(11):1079-1085 (2001).
Huber, K.M., et al., “Role for Rapid Dendritic Protein Synthesis in Hippocampal mGluR-Dependent Long-Term Depression,”Science288:1254-1256 (2000).
Spooren, W.P.J.M., et al., “Novel Allosteric Antagonists Shed Light on mglu5Receptors and CNS Disorders,”TRENDS in Pharmacological Sciences 22(7):331-337 (2001).
Bear Mark F.
Huber Kimberly M.
Warren Stephen T.
Brown University
Emory University
Hamilton Brook Smith & Reynolds P.C.
Jones Dwayne
LandOfFree
Methods of treating disorders with Group I mGluR antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating disorders with Group I mGluR antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating disorders with Group I mGluR antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3425344